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Summary 
A critical hallmark of adaptive immune responses is the rapid and extensive 
expansion of lymph nodes. During this process, the complex internal structure 
of the organs is maintained revealing the existence of mechanisms able to 
balance lymph node integrity with structural flexibility. This article reviews the 
extensive architectural remodeling that occurs within lymph nodes during 
adaptive immune responses and how it is regulated by dendritic cells (DCs). 
In particular we focus on previously unappreciated functions of DCs in 
coordinating remodeling of lymph node vasculature, expansion of the 
fibroblastic reticular network and maintenance of lymphoid stromal 
phenotypes. Our increased understanding of these processes indicates that 
DCs need to be viewed not only as key antigen-presenting cells for 
lymphocytes but also as broad-acting immune sentinels that convey signals to 
lymphoid organ stroma and thereby facilitate immune response initiation at 
multiple levels.  
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1. Introduction 
Lymph nodes act as pathogen filters, sites of encounter between antigen-
presenting cells and lymphocytes and as environments for clonal expansion of 
antigen-specific T and B cells (1, 2). Key to all these processes is the 
architecture of the lymph node, which is supported by a complex 
interconnecting scaffold of non-haematopoetic stromal cells, including 
specialised fibroblasts, lymphatic endothelial cells and blood endothelial cells 
(1, 3). In addition to providing the physical infrastructure, stromal subsets help 
define different territories within lymph nodes. T cell areas contain fibroblastic 
reticular cells (FRCs) that account for 30-50% of total lymph node stroma and 
stretch throughout the paracortex forming a complex interconnected cellular 
network (1-3). FRCs produce the CCR7 ligands, CCL19 and CCL21, that 
attract T cells and promote their migration, as well as IL-7, which acts as a T 
cell trophic signal (4, 5). B cell follicles are supported by follicular dendritic 
cells (FDCs), a rarer stromal cell subset that produces CXCL13 along with 
growth factors such as BAFF necessary for the proliferation and maintenance 
of B cells (6). Additionally present throughout the node are specialized blood 
vessels, termed high endothelial venules (HEVs), that support the immigration 
of T and B cells from the bloodstream and respond to inflammatory stimuli to 
increase such traffic (7). After entry into the lymph node via HEVs, 
lymphocytes utilise the stromal cell networks to migrate to their correct 
anatomical location and to meet antigen-presenting cells (2). 
Dendritic cells (DCs) are the classical antigen-presenting cells in lymphoid 
organs (8). Some DCs are constitutively resident in those organs and 
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differentiate locally from a blood-borne precursor (9, 10). Other DCs are 
termed migratory and represent lymph-borne immigrants from peripheral 
tissues (11). DC migration happens constitutively but is markedly accelerated 
after infection or inflammation (8, 11). Within the lymph node, immigrant DCs 
bearing antigens acquired in the periphery, or resident DCs presenting 
antigens acquired from afferent lymph, become strategically positioned on the 
stromal network for scanning by naïve T cells (12). T cells that encounter 
foreign antigen, together with appropriate co-signals, proliferate, differentiate 
and home to peripheral tissues in order to eliminate the challenge (8).  
One of the hallmarks of the immune reaction is massive lymph node 
expansion, with organ cellularity and physical size increasing 5-10 fold 
following immunisation or infection (1) It is becoming increasingly clear that 
DCs play a key role in this process by conveying key signals to stromal 
components that are required to initiate the remodeling of lymph node 
architecture and to support organ expansion. Thus, DCs not only deliver 
foreign antigens and promote activation and clonal expansion of T cells but 
also modify the lymph node environment to support that expansion.  Here we 
specifically discuss the role of DCs in lymph node architecture and in its 
remodelling at the outset of immune responses. 
2. DCs in antigen presentation to T cells 
An adaptive immune response requires T cells to become stimulated in 
response to foreign antigens processed and presented by DCs. Sessile DCs 
present in tissues throughout the body continuously monitor their 
microenvironment for signs of tissue damage or infection. In response to 
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these signs, DCs become motile and traffic to lymph nodes (8, 11, 13). A key 
molecule upregulated during this transition is the chemokine receptor CCR7. 
CCR7 has long been accepted as the critical receptor for entry of DCs into 
lymph nodes (14) but is now also known to be important for the mobilization of 
DCs within the tissues and for supporting their haptotactic migration towards 
afferent lymphatics at the start of their journey (15). Whilst CCR7 undoubtedly 
controls the directional migration of DCs, our understanding of mechanisms 
controlling DC entry into lymph nodes has been recently expanded to include 
additional layers of complexity. The C-type lectin CLEC-2, whose expression 
on DCs is greatly increased following exposure to inflammatory stimuli (16-
18), has been shown to help promote the migratory behavior of the cells (16). 
CLEC-2 interacts with the glycoprotein ligand podoplanin (PDPN), also known 
as gp38, which is constitutively expressed on lymphatic endothelium and 
fibroblastic reticular cells (3, 19), on which DCs crawl en route to and within 
the lymph node paracortex (20). Triggering of CLEC-2 by PDPN promotes 
formation of actin-rich protrusions in DCs, via the activation of Vav and Rac1 
(16). These protrusions allow DCs to spread along stromal scaffolds and 
support DC motility (16).  
Another mechanism controlling lymph node entry of DCs operates at the level 
of the subcapsular sinus and involves the atypical chemokine receptor CCRL1 
(21). CCRL1 is expressed by lymphatic endothelial cells that line the celling 
but not the floor of the subcapsular sinus (21). CCRL1 binds, sequesters and 
induces the degradation of CCL21 and CCL19, creating a gradient (21). This 
allowing incoming antigen-laden DCs to keep moving towards the inner areas 
of the node an provides an elegant explanation as to how they reach the 
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paracortex to find and prime naïve T cells. 
Lymph arriving at lymph nodes via afferent lymphatic vessels flows beneath 
the capsule in the subcapsular sinus. Its ability to carry microbial debris and 
live organisms means that it can serve a rich source of antigens emanating 
from sites of infection. It had been suggested that DCs resident in the lymph 
node can acquire small soluble antigens arriving via the conduit network (see 
below) (22, 23). More recently, it has been found that a subset of lymph node-
resident DCs can also directly sample the contents of the subcapsular sinus 
and thereby acquire even large size pathogen material such as bacteria or 
viruses that drain from sites of infection via the afferent lymph (24). Antigen 
acquisition by lymph node-resident DCs allows for rapid initiation of T cell 
responses to pathogens and complements antigen presentation by migratory 
DCs. 
3. DCs in the filtering function of lymph nodes 
In addition to acting as sites of antigen presentation, lymph nodes also act as 
filters for lymph draining from tissue. The inner sinus lining acts as a physical 
barrier between the lymph and the rest of the node. Migratory DCs and 
activated lymphocytes actively migrate through this barrier in order to reach 
the inner areas of the node. In contrast, soluble factors such as chemokines 
and cytokines that are sufficiently small (<70kDa) are permitted to flow 
through the lymph node confined within a network of conduits (25).  Conduits 
are essentially small interconnecting tubes constructed out of collagen and 
other basement membrane components (23, 25, 26) excreted by FRCs. 
These extracellular matrix components are then bundled and held together by 
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the FRCs wrapping their cell bodies around them (19, 23). Conduit size 
exclusion is controlled by a specialised lymphatic endothelial cell population 
that lines the celling and floor of the sinus and that expresses the glycoprotein 
PLVAP (27). PLVAP allows these endothelial cells to forms diaphragms, 
effectively closing off the underlying conduit network to large molecules (27). 
There is also evidence that PLVAP+ channels serve as a route for 
transmigrating leukocytes arriving via the afferent lymph as lymph nodes from 
mice lacking PLVAP become severely distorted and display an accumulation 
of activated B cells in enlarged follicles and a reduction in T cells (27). 
If afferent lymph can carry live microbes after infection, how are they 
prevented from disseminating systemically? The PLVAP+ cells and the 
conduit system act as one barrier. Another key barrier operates at the level of 
the subcapsular sinus where specialised CD169+ macrophages take up 
bacteria and viruses and destroy them (28, 29) In addition CD169+ 
macrophages orchestrate an innate immune response that reinforces the 
subcapsular sinus “firewall” and contributes to preventing pathogen 
dissemination (30). Finally, subcapsular sinus macrophages also serve as 
antigen-presenting cells for B cells and transfer antigens captured from the 
incoming afferent lymph to B cells that residing in follicles just beneath the 
sinus (28, 31, 32). Notably, it has recently been found that the transfer of 
antigen to B cells is aided by a process of macrophage migration into the 
follicles, which is triggered by the arrival of immigrant DCs (33). However, 
large scale macrophage re-localisation causes temporary loss of the 
protective macrophage layer, which, in mice, can take 28 days to be 
reinstated (33). During this period, subcapsular sinus firewall integrity and 
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further B cell responses are compromised, resulting in vulnerability to 
secondary infection (33). 
4. DCs in maintenance and growth of the lymph node vascular network 
Lymphocytes continuously recirculate between the blood and the lymph 
nodes {Lammermann:2008bk, Young:1999ww}. Key to this process are 
HEVs, specialized parts of the vasculature that favour lymphocyte egress 
from the circulation and serve as the ports of lymphocyte entry into nodes (7). 
It is now clear that DCs are important regulators of the conversion of blood 
endothelial cells into HEV cells. Close contact between lymph node resident 
DCs and HEVs and signaling via LTβR maintains the expression of 
specialized HEV markers such as GLYCAM1 even though others, such as 
CD31 and VE-cadherin, are DC-independent (35).  Notably, in the absence of 
DCs, the HEV phenotype is lost and the endothelium reverts to an immature 
phenotype unable to support T and B cell trafficking (35).  
During lymph node expansion, growth of the HEV network is a required and 
important step to provide additional entry points for circulating lymphocytes. In 
the absence of vascular growth, lymph nodes expansion is significantly 
attenuated (36). Like maintenance, endothelial proliferation is dependent on 
DCs and other myeloid cell populations. The stimulatory effect of DCs on 
vascular growth is so pronounced that transfer of DCs is sufficient to promote 
HEV proliferation (36). The signal for vascular proliferation is received via 
VEGFR engagement by VEGF. Dendritic cells are however not the source of 
this growth factor. Through the use of VEGF LacZ reporter mice and mRNA 
analysis of lymph node stromal cell populations, it was shown that it is in fact 
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FRCs that express VEGF to provide the proliferative cue (37). Some FRCs 
ensheath HEVs and behave as a specialised pericyte population that remains 
connected to the FRC network. DCs closely associate with the FRC network 
and provide ligands for lymphotoxin-β receptor, the signaling of which leads to 
the production of VEGF by FRCs (38, 39). This DC-FRC communication 
appears to be direct as DCs are able to elicit the same effect on fibroblast cell 
lines in coculture experiments in vitro (38). There are further reports that 
support the notion that the presence of DCs controls lymph node size. A 
recent study of found that expression of diphtheria toxin receptor in DCs can 
lead to an unexpected dearth of these cells, in particular of the migratory 
subtype, in lymph nodes (40). While the reason for this observation remains 
unclear, it is correlated in all cases with lymph node hypocellularity (40). One 
potential explanation is the lack of lymphotoxin-β receptor ligands and a 
failure of DCs to regulate levels of VEGF produced by FRCs, thereby 
reducing the vascular network and the number of entry sites for lymphocytes.  
Permitting large numbers of lymphocytes to enter lymph nodes following 
inflammation appears at odds with the ability of HEVs to maintain an effective 
barrier between the blood and the lymphoid tissue. One solution to these 
seemingly contradictory functions is again found in the crosstalk between 
FRCs and the endothelium (Fig. 1). In inflamed lymph nodes, at the same 
time as numerous lymphocytes traffic through HEVs, platelets also leak from 
the blood into the perivascular space. Here, they immediately encounter 
FRCs that ensheath the endothelium. The FRCs in this space, similar to 
FRCs through the rest of the network, express high levels of PDPN that 
triggers CLEC-2, which is constitutively expressed at high levels on platelets 
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(41) CLEC-2 signalling via the kinase Syk leads to the release of sphingosine-
1-phosphate (S1P) from platelets, which acts on the endothelium to induce 
upregulation of VE-cadherin, a critical junctional protein (42). The upregulation 
of VE-cadherin is sufficient to reinforce the endothelial cell-cell junctions and 
maintain the barrier function of the HEV (42), preventing further leakage of 
blood components into the tissue. In genetic models of ablation of either 
PDPN from FRCs or CLEC-2 from platelets, severe bleeding within the lymph 
nodes occurred, a defect which could be rescued by the transfusion of CLEC-
2-sufficient platelets (42).  
5. DCs in stretching of the FRC network. 
In response to inflammation, HEV function is increased to facilitate ingress of 
lymphocytes from the blood while signals that permit lymphocyte egress from 
lymph nodes are downregulated, a process termed lymph node shutdown 
(43). The net result is an increase in numbers of naïve lymphocytes 
accumulating in the reacting lymph node and this is what initially increases 
total lymph node cellularity before antigen-specific activation results in clonal 
proliferation of both B and T cells. As a result of both lymphocyte trapping and 
proliferation, lymph node cellularity rapidly increases, placing pressure and 
strain on the stromal architecture and forcing its remodeling (44, 45, 46). 
It had been assumed that the enlargement of lymph nodes occurs through the 
synchronised and coordinated proliferation of stromal and lymphocytic 
components (3, 44). This does seem to be true for the proliferation of blood 
endothelial cells, which begins very early in reactive lymph nodes (36). 
However, it is not the case for fibroblastic stroma. In fact, when stromal cell 
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subsets and lymphocytes are enumerated over time following immunisation, a 
lag in the proliferation of FRCs can be observed (44, 45). The length of this 
lag depends on the immune stimulus but can be as much as two days, during 
which time a marked increase in lymph node size has already taken place 
(44, 45). How, then, does the lymph node accommodate increased cellularity 
in this early phase of an immune response without increasing numbers of 
FRCs? The FRC network is a highly contractile structure and in fact the size 
of the lymph node can be controlled via the tuning of contractility of FRCs, 
notably, by DCs (Fig. 2).  
Contractility in FRCs is driven by the activity of PDPN. We, and others have 
found that PDPN constitutively signals to drive actomyosin contractility without 
the requirement for engagement by an external ligand (45, 46). In this state, 
the cytoplasmic tail of PDPN is serine phosphorylated (45, 47) and binds to 
ezrin/radixin/moesin proteins (45, 48), connecting the plasma membrane to 
the underlying actin cytoskeleton. PDPN signaling also promotes RhoA/C 
activity, and activation of the RhoA/C effector Rho kinase (ROCK), which 
leads to phosphorylation of myosin light chain (MLC2) and the generation of 
contractile actin filaments (49) It is not yet clear which kinase is responsible 
for the phosphorylation and activation of PDPN and, furthermore, the direct 
connection between PDPN and RhoA activity remains to be fully 
characterised. Indeed, in one study, the ability of PDPN to drive contractility 
appeared independent of the cytoplasmic tail, raising the question of whether 
additional mechanisms exist to permit RhoA signaling (46). Either way, this 
signaling and the associated contractile activity of PDPN is tempered by 
sequestration within cholesterol-rich lipid rafts, which uncouples PDPN from 
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ezrin. This likely occurs through PDPN binding to inhibitory partners present in 
the membrane microdomain, including the hyaluronic acid receptor CD44, 
which itself can also drive contractility. Evidence suggests that when 
podoplanin is bound to CD44 both proteins become confined to cholesterol-
rich lipid rafts and this inhibits contractility induced by either one (50). 
The critical switch to drive PDPN into lipid rafts and thereby inhibit 
podoplanin-driven contractile activity is delivered by DCs in the form of CLEC-
2. As already mentioned, CLEC-2 is upregulated on DCs following 
inflammation and helps promote DC motility(16). But CLEC-2 is also a potent, 
short-acting inhibitor of PDPN (45, 46, 51) an unusual example of reciprocal 
signaling that puts in question traditional definitions of ligand and receptor. 
Upon binding to CLEC-2, PDPN becomes clustered and sequestered into 
cholesterol-rich lipid rafts where it is rendered inactive (45, 52). This 
mechanism has also been shown in the skin, where CLEC-2+ platelets inhibit 
podoplanin-driven migration of keratinocytes (51). The biological 
consequences of this unusual mode of regulation are dramatic. Increased 
availability of CLEC-2+ DCs in the lymph node at the outset of an immune 
response results in an abrupt loss of tension through the actomyosin 
cytoskeleton of the FRCs (45) effectively allowing FRC network stretching and 
lymph node expansion. Indeed, genetically engineered mice in which CLEC-2 
expression is selectively ablated on DCs  (CD11cCreClec1bfl/fl mice) show 
significantly reduced lymph node expansion following immunization compared 
to controls (45, 46). Similarly, lasting inhibition of PDPN activity using anti-
PDPN antibody treatment in vivo results in increased lymph nodes following 
immunization and an increase in proliferation of antigen-specific T cells(46). 
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These findings indicate that PDPN activity is an important factor in the 
regulation of lymph node size and potentially the scale of adaptive immune 
responses.  
6. DCs in the expansion of the stromal network 
Despite the remarkable flexibility of the stromal cell network, there comes a 
point, between 2-5 days after initiation of a response, where stretching is no 
longer sufficient to support lymph node expansion. Beyond this stage, an 
increased number of fibroblastic stromal cells are required. There are many 
potential cues to initiate proliferation of the existing FRC network. Perhaps 
proliferation is initiated as the physical limit of stromal cell length is maximised 
and the point at which the interconnected network is in danger of becoming 
detached and disconnected. Podoplanin activity may also play a role in 
controlling the proliferation of FRCs as FRCs from PDPN-/- mice proliferate 
more in culture that wildtype counterparts (46). As PDPN signaling is inhibited 
by CLEC-2, it is reasonable to suppose that CLEC-2+ DCs not only provide 
the signal that causes FRC network stretching but also promote FRC 
proliferation. Consistent with that notion, increases in FRC number following 
LPS challenge in vivo are attenuated in CD11cCreClec1bfl/fl mice (46). The 
number of CLEC-2+ DCs is at its peak during the acute phase of FRC 
stretching but it has also been reported that CLEC-2 can be cleaved and 
retain bioactivity in soluble form (53) so that there are potentially additional 
sources of CLEC-2 at later phases of LN expansion, including soluble CLEC-2 
released from platelets. As FRCs relax their cytoskeleton and stretch to 
accommodate increased lymph node size, they increase in size (44, 45). This 
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change may be part of the set of cues that initiates the proliferation and 
expansion of the FRC network. FRCs may also respond directly to 
inflammatory stimuli prior to stretching priming them to proliferate, although it 
may also be possible that even a small change in physical tension at these 
early stages is the initiating factor for proliferation. 
We know that fibroblastic stroma in the steady state can derive from a variety 
of sources (54-56) but the relative contribution of each of these sources to 
lymph node expansion during adaptive immune responses is unclear. 
Proliferation of pre-existing FRCs can be documented by uptake of EdU or 
similar assays that identify proliferating cells (44). Other data suggest a 
contribution from recruited percursors (57). In particular, the adipose tissue of 
the fat pad, within which most lymph nodes are found embedded has been 
shown to act as a source of stromal precursors, both in development (58) and 
during lymph node expansion in adult mice (54).  In development, it has been 
described that a common mesenchymal precursor cell is able to give rise to 
both fibroblastic stroma in the developing lymph node and to adipocytes (59). 
The fate of these stromal precursors is dependent on the balance of signals 
received by the differentiating cells. LTβR stimulation promotes their 
differentiation into lymphoid tissue stromal cells (59). As DCs provide a rich 
source of ligands for LTβR, they could play a role in the conversion of 
adipose-derived, mesenchymal-precursors into new FRCs during lymph node 
expansion (54). In a series of transplant experiments, adipose-derived 
infiltrating stromal cells invaded deeply into the lymph nodes and positioned 
themselves in close proximity to the FRC network, as determined by PDPN 
and ER-TR7 staining (54). It is therefore possible that these cells might 
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combine with the existing reticular network to extend and expand the stromal 
architecture to allow further lymph node expansion.  
There may also be a conversion of other stromal cell subsets in order to 
expand the stromal networks during lymph node expansion. In peripheral 
tissues such as the skin, gut, and in tumours, inflammation can induce the 
conversion of resident fibroblast populations into podoplanin-expressing 
stromal cells (60, 61), expressing IL-7, CCL19 and CCL21. This conversion 
was found to be dependent on Gr1+ myeloid cell populations (60). There is 
therefore a precedent for the conversion of mesenchymal cells into FRC-like 
fibroblasts, and potentially signaling from myeloid cells such as DCs that drive 
this differentiation. Similar mechanisms may be in action within lymph nodes.  
There are significant similarities in gene expression between FRCs and a 
proposed lymph node specific pericyte population termed ‘double negative’ 
(DN) cells, for example, the expression of chemokines such as CXCL14, 
cytokines such as Flt3L, and markers of fibroblastic function such as αSMA 
(19), potentially making DN cells a pre-FRC. Fibroblasts throughout different 
tissues display remarkable plasticity and ability to respond to the local 
microenvironment (62-64). It is conceivable that DN cells under the right 
conditions could therefore differentiate and contribute to the growing FRC 
network.  
There is also precedent for the proliferation, conversion and differentiation of 
neighbouring cells in increasing FDC numbers during expansion of B cell 
follicles. Lineage tracing experiments revealed that marginal reticular cells 
(MRCs) (55) residing immediately below the subcapsular sinus, contributed to 
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the expanding FDC population. Like other stromal cell subsets, MRCs 
express high levels of PDPN, CXCL13 and RANK but, unlike T zone FRCs, 
they also express MAdCAM1. During lymph node expansion, MRCs 
proliferate and migrate into the follicles where they adopt an FDC phenotype 
(55). Interestingly, the proliferation of MRCs still occurs in Rag-/- mice, 
meaning that the increasing number of B cells is most likely not the stimulus 
for MRC proliferation (55). preFDCs can also be found in the form of 
PDGFRβ+ pericytes (56). PDGFRβ-Cre reporter mice showed labeling of 
FDCs in B cell follicles of the spleen, whereas deletion of PDGFRβ+ progeny 
resulted in a loss of FDCs (56). PDGFRβ+ pericytes in other tissues can also 
convert to FDC, able to support the accumulation and organization of B cells 
during the formation of tertiary lymphoid structures at inflammatory sites (56).   
There is some evidence that like FDCs, FRCs could also be derived via the 
conversion of another stromal subsets. Endosialin/TEM1 (CD248) is a 
fibroblast marker (65, 66) observed in inflammatory settings such as 
rheumatoid arthritis (67). In resting lymph nodes CD248 expression is 
confined to the capsule but, following immunization, it is observed throughout 
the lymph node although, interestingly, shows little or no colocalisation with 
podoplanin (68). This lymph node-wide expression is relatively short-lived and 
disappears within 2-3 weeks of immunization. The identity and origin of the 
appearing CD248+ cells is still unclear, however, CD248 knockout mice 
exhibit significantly attenuated lymph node expansion at 5-7 days post 
immunization (68). CD248 expression is regulated by hypoxia (69) and in vitro 
at least has significant effects to promote proliferation and motility of 
mesenchymal cells (65, 68). CD248+ cells might be fibroblasts from the 
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capsule, double negative (DN) stroma or an infiltrating precursor population 
that have not yet acquired PDPN expression, but may with additional signals 
from the leukocyte population, contribute to the expanding FRC network. 
7. DCs in recovery of normal lymph node architecture 
In addition to promoting the production of VEGF by FRCs, LTβR ligands 
secreted by DCs have a profound influence on FRC viability, survival and 
adhesion (39). LNs lacking DCs lose FRC network integrity and fail to 
maintain adequate FRC numbers (39). This tells us about the steady state of 
LN architecture but also provides potential mechanisms to resolve the issue of 
reducing the numbers of FRCs as the immune response and the inflammation 
are resolved and the lymph node shrinks back to the original size.  Recent 
work has also shown that even quick resolution of acute infection can leave a 
long lasting ‘scar’ in local tissue and unbalance future immune responses 
(70). This may involve damage to the local lymphatic system with lymphatic 
vessels that become chronically ‘leaky’ and lead to redirection of afferent 
lymph cells, including DCs, into adipose tissue (70), This immunological 
scarring may contribute to the development of chronic inflammatory diseases. 
Indeed, in the case of chronic infections such as HIV, lymph node damage 
and fibrosis are commonly observed (71, 72). Reduced numbers of T cells 
diminishes T-cell derived LTβ, which, like that of DCs, helps maintain the FRC 
network. Loss of T cells during the infection therefore causes a corresponding 
loss of FRCs. Since FRCs produce IL-7 to promote survival of T cells, a 
negative spiral of loss of lymphoid tissue function ensues. To make matters 
worse, increased TGFβ signaling from regulatory T cells induces the 
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diminishing population of FRCs to overproduce extracellular matrix proteins 
which, over time, causes tissue fibrosis, further restricting access of T cells to 
the source of IL-7 (3). Numbers of DCs tend to also be reduced in HIV 
infection (73). Knowing that DCs play important roles in the maintenance of 
the FRC network (39), therapeutic strategies to rescue the DC population may 
have significant benefit.  
8. Concluding remarks 
DCs have traditionally been viewed as the sentinels of the immune system. 
The transport and presentation of antigen by DCs provides the critical signal 
for the initation of adaptive immune responses. Our understanding of the role 
of DCs is now significantly broadened. The same sentinels communicate 
directly with the stromal cells of lymph nodes, maintaining their integrity and 
“priming” their ability to accommodate lymph node expansion. We understand 
some of the molecular players involved in the crosstalk between DCs and 
stroma, in particular the axes of LTβ/LTβR and CLEC-2/PDPN signaling. 
There are likely to be several others and their elucidation will help our 
understanding of a process that is emerging to be just as critical to immunity 
as the delivery of antigen and the trafficking of leucocytes. 
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